$STRO
SUTRO BIOPHARMA, INC.

2023 Q3 Form 10-Q Financial Statement

#000095017023041416 Filed on August 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $16.92M $10.41M
YoY Change -32.7% -62.94%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $15.27M $15.00M
YoY Change 4.28% -0.95%
% of Gross Profit
Research & Development $45.67M $41.59M
YoY Change 44.0% 28.64%
% of Gross Profit
Depreciation & Amortization $1.740M $1.731M
YoY Change 21.0% 23.91%
% of Gross Profit
Operating Expenses $60.94M $56.59M
YoY Change 31.45% 19.2%
Operating Profit -$44.01M -$46.18M
YoY Change 107.52% 138.29%
Interest Expense $2.510M $8.248M
YoY Change 45.76% -299.56%
% of Operating Profit
Other Income/Expense, Net -$5.940M -$442.0K
YoY Change
Pretax Income -$47.45M -$38.37M
YoY Change 143.46% 63.21%
Income Tax $1.800M $200.0K
% Of Pretax Income
Net Earnings -$49.28M -$38.52M
YoY Change 152.89% 48.1%
Net Earnings / Revenue -291.21% -370.0%
Basic Earnings Per Share -$0.81 -$0.64
Diluted Earnings Per Share -$0.81 -$0.64
COMMON SHARES
Basic Shares Outstanding 60.53M 60.42M
Diluted Shares Outstanding 60.60M 60.34M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $355.2M $391.6M
YoY Change 9.55% 73.57%
Cash & Equivalents $81.83M $235.1M
Short-Term Investments $273.3M $156.5M
Other Short-Term Assets $9.500M $10.34M
YoY Change -14.14% 26.08%
Inventory
Prepaid Expenses
Receivables $16.63M $9.999M
Other Receivables $0.00 $0.00
Total Short-Term Assets $381.3M $412.0M
YoY Change 10.01% 24.27%
LONG-TERM ASSETS
Property, Plant & Equipment $22.34M $23.64M
YoY Change -7.98% 0.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.268M $3.268M
YoY Change 70.12% 70.12%
Total Long-Term Assets $50.48M $52.91M
YoY Change -6.77% -2.21%
TOTAL ASSETS
Total Short-Term Assets $381.3M $412.0M
Total Long-Term Assets $50.48M $52.91M
Total Assets $431.7M $464.9M
YoY Change 7.74% 20.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.525M $3.856M
YoY Change -55.6% -69.32%
Accrued Expenses $11.37M $9.509M
YoY Change 9.53% 22.73%
Deferred Revenue $23.98M $18.04M
YoY Change 50.65% 177.9%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $7.100M $10.20M
YoY Change -43.2% -18.42%
Total Short-Term Liabilities $73.61M $67.13M
YoY Change 26.28% 50.6%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $245.8M $243.1M
YoY Change 184712.03% 171068.31%
Total Long-Term Liabilities $245.8M $243.1M
YoY Change 3454.08% 2349.94%
TOTAL LIABILITIES
Total Short-Term Liabilities $73.61M $67.13M
Total Long-Term Liabilities $245.8M $243.1M
Total Liabilities $319.4M $310.2M
YoY Change 86.8% 75.68%
SHAREHOLDERS EQUITY
Retained Earnings -$590.5M -$541.2M
YoY Change 41.27% 35.81%
Common Stock $702.8M $695.9M
YoY Change 8.28% 14.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $112.3M $154.7M
YoY Change
Total Liabilities & Shareholders Equity $431.7M $464.9M
YoY Change 7.74% 20.56%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$49.28M -$38.52M
YoY Change 152.89% 48.1%
Depreciation, Depletion And Amortization $1.740M $1.731M
YoY Change 21.0% 23.91%
Cash From Operating Activities -$33.50M -$31.20M
YoY Change -150.87% 879.13%
INVESTING ACTIVITIES
Capital Expenditures $320.0K $1.604M
YoY Change -143.36% -172.91%
Acquisitions
YoY Change
Other Investing Activities -$113.7M $67.76M
YoY Change 47.08% 35.21%
Cash From Investing Activities -$114.0M $66.16M
YoY Change 46.11% 38.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -5.740M 137.7M
YoY Change -119.23% 2409.77%
NET CHANGE
Cash From Operating Activities -33.50M -31.20M
Cash From Investing Activities -114.0M 66.16M
Cash From Financing Activities -5.740M 137.7M
Net Change In Cash -153.3M 172.6M
YoY Change -967.64% 243.77%
FREE CASH FLOW
Cash From Operating Activities -$33.50M -$31.20M
Capital Expenditures $320.0K $1.604M
Free Cash Flow -$33.82M -$32.80M
YoY Change -150.79% 3226.47%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001382101
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38662
dei Entity Registrant Name
EntityRegistrantName
SUTRO BIOPHARMA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-0926186
dei Entity Address Address Line1
EntityAddressAddressLine1
111 Oyster Point Blvd
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
881-6500
dei Security12b Title
Security12bTitle
Common stock, $0.001 par value
dei Trading Symbol
TradingSymbol
STRO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
60527043
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
235095000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47254000
CY2023Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
123198000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
255090000
CY2023Q2 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
33349000
CY2022Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
32020000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9999000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7122000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10344000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11667000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
411985000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
353153000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23636000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
24621000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25138000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26443000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3268000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1855000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
872000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
872000
CY2023Q2 us-gaap Assets
Assets
464899000
CY2022Q4 us-gaap Assets
Assets
406944000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3856000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4797000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9509000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13142000
CY2023Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
18036000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
16759000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5934000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4585000
CY2023Q2 us-gaap Debt Current
DebtCurrent
10197000
CY2022Q4 us-gaap Debt Current
DebtCurrent
12500000
CY2023Q2 stro Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
19593000
CY2022Q4 stro Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
14764000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
67125000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
66547000
CY2023Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
79880000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
89885000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
26526000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
29574000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3771000
CY2023Q2 stro Deferred Royalty Obligation Related To Sale Of Future Royalties Noncurrent
DeferredRoyaltyObligationRelatedToSaleOfFutureRoyaltiesNoncurrent
136653000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
119000
CY2023Q2 us-gaap Liabilities
Liabilities
310184000
CY2022Q4 us-gaap Liabilities
Liabilities
189896000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60471041
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60471041
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
57499541
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
57499541
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
60000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
58000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
695828000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
670223000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
16000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-618000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-541189000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-452615000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
154715000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
217048000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
464899000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
406944000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10412000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
28096000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
23086000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33993000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41592000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32332000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
80991000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
62322000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14999000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15143000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30511000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30182000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
56591000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
47475000
us-gaap Operating Expenses
OperatingExpenses
111502000
us-gaap Operating Expenses
OperatingExpenses
92504000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-46179000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-19379000
us-gaap Operating Income Loss
OperatingIncomeLoss
-88416000
us-gaap Operating Income Loss
OperatingIncomeLoss
-58511000
CY2023Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
2842000
CY2022Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
197000
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
5402000
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
313000
CY2023Q2 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
8321000
CY2022Q2 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-3736000
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
1329000
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-3173000
CY2023Q2 stro Non Cash Interest Expense Related To The Sale Of Future Royalties
NonCashInterestExpenseRelatedToTheSaleOfFutureRoyalties
442000
stro Non Cash Interest Expense Related To The Sale Of Future Royalties
NonCashInterestExpenseRelatedToTheSaleOfFutureRoyalties
442000
CY2023Q2 stro Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
-2915000
CY2022Q2 stro Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
-594000
stro Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
-5901000
stro Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
-1251000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38373000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23512000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-88028000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-62622000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2500000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
546000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2500000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-38524000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-26012000
us-gaap Net Income Loss
NetIncomeLoss
-88574000
us-gaap Net Income Loss
NetIncomeLoss
-65122000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.39
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60339475
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60339475
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46957196
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46957196
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59535918
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59535918
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46729663
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46729663
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-38524000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-26012000
us-gaap Net Income Loss
NetIncomeLoss
-88574000
us-gaap Net Income Loss
NetIncomeLoss
-65122000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
123000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-204000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
634000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1042000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38401000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26216000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-87940000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-66164000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
217048000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
314000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1097000
CY2023Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
451000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6021000
CY2023Q1 stro Stock Issued During Period Value Through At The Market Sale
StockIssuedDuringPeriodValueThroughAtTheMarketSale
10923000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
511000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-50050000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
185413000
CY2023Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
6000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6661000
CY2023Q2 stro Stock Issued During Period Value Through At The Market Sale
StockIssuedDuringPeriodValueThroughAtTheMarketSale
1048000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
123000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-38524000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
154715000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
252564000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
180000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1006000
CY2022Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
404000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6974000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-838000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-39110000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
220372000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
CY2022Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
9000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6696000
us-gaap Repayments Of Debt
RepaymentsOfDebt
3125000
stro Proceeds From Sale Of Future Royalties Net Of Issuance Costs
ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts
139744000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
314000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
182000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
457000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
413000
CY2022Q2 stro Stock Issued During Period Value Through At The Market Sale
StockIssuedDuringPeriodValueThroughAtTheMarketSale
8213000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-204000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-26012000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
209058000
us-gaap Profit Loss
ProfitLoss
-88574000
us-gaap Profit Loss
ProfitLoss
-65122000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3346000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2724000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3628000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-913000
us-gaap Share Based Compensation
ShareBasedCompensation
12682000
us-gaap Share Based Compensation
ShareBasedCompensation
13670000
stro Noncash Lease Expenses
NoncashLeaseExpenses
1305000
stro Noncash Lease Expenses
NoncashLeaseExpenses
1325000
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
1329000
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-3173000
stro Non Cash Interest Expense On Deferred Royalty Obligation
NonCashInterestExpenseOnDeferredRoyaltyObligation
442000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-106000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-13000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2877000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
85217000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
90000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
81000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-659000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
836000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-3633000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-3669000
stro Increase Decrease In Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherLiabilities
1150000
stro Increase Decrease In Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherLiabilities
1072000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-8728000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
90994000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1699000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
928000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-92186000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38441000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
141361000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
14938000
stro Proceeds From Maturities Of Marketable Securities
ProceedsFromMaturitiesOfMarketableSecurities
268460000
stro Proceeds From Maturities Of Marketable Securities
ProceedsFromMaturitiesOfMarketableSecurities
70409000
stro Proceeds From Sales Of Marketable Securities
ProceedsFromSalesOfMarketableSecurities
9055000
stro Proceeds From Sales Of Marketable Securities
ProceedsFromSalesOfMarketableSecurities
29179000
stro Payments To Acquire Equipment And Leasehold Improvements
PaymentsToAcquireEquipmentAndLeaseholdImprovements
2546000
stro Payments To Acquire Equipment And Leasehold Improvements
PaymentsToAcquireEquipmentAndLeaseholdImprovements
3753000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
133608000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
80897000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
11971000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
8595000
us-gaap Repayments Of Debt
RepaymentsOfDebt
6250000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1097000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1006000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
146419000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6245000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
187841000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
48701000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
48126000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
31286000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
235967000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
79987000
us-gaap Interest Paid Net
InterestPaidNet
722000
us-gaap Interest Paid Net
InterestPaidNet
998000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
141000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
392000
stro Financing Component Associated With Program Fees
FinancingComponentAssociatedWithProgramFees
5075000
stro Issuance Costs Related To Deferred Royalty Obligation In Accrued Expenses
IssuanceCostsRelatedToDeferredRoyaltyObligationInAccruedExpenses
3536000
stro Issuance Costs Included In Accounts Payable
IssuanceCostsIncludedInAccountsPayable
382000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1. Organization and Principal Activities</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Description of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Sutro Biopharma, Inc. (the “Company”), is a clinical-stage oncology company developing site-specific and novel-format antibody drug conjugates, or ADCs. The Company was incorporated on </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">April 21, 2003</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> and is headquartered in </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">South San Francisco</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">California</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company operates in </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> business segment, the development of biopharmaceutical products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">At-The-Market Sales</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">During the three and six months ended June 30, 2023, the Company sold an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">216,036</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares</span><span style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">and </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,857,410</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares, respectively, of its common stock through its At-the-Market Facility (“ATM Facility”) pursuant to its Open Market Sales Agreement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">SM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> dated April 2, 2021 with Jefferies LLC (“Jefferies”), as sales agent (the “Sales Agreement”).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">During the three and six months ended June 30, 2023, the gross proceeds from these sales were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, respectively, before deducting fees of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, respectively, resulting in net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, respectively, to the Company.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Liquidity</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company has incurred significant losses and has negative cash flows from operations. As of June 30, 2023, the Company had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">541.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million. Management expects to continue to incur additional </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">substantial</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> losses in the foreseeable future as a result of the Company’s research and development and other operational activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of June 30, 2023, the Company had unrestricted cash, cash equivalents and marketable securities of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">358.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and equity securities of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">33.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, consisting solely of common stock of Vaxcyte, which are available to fund future operations. The Company will need to raise additional capital to support the completion of its research and development activities and to support its operations.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company believes that its unrestricted cash, cash equivalents, marketable securities and equity securities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> as of June 30, 2023 will enable the Company to maintain its operations for a period of at least </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> months following the filing date of its condensed financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2003-04-21
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-541200000
us-gaap Substantial Doubt About Going Concern Within One Year
SubstantialDoubtAboutGoingConcernWithinOneYear
false
CY2023Q2 stro Unrestricted Cash Cash Equivalents And Marketable Securities At Carrying Value
UnrestrictedCashCashEquivalentsAndMarketableSecuritiesAtCarryingValue
358300000
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
357790000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
21000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
235095000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
79115000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
872000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
872000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
235967000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
79987000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
357806000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
299026000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
10000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
626000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
298410000
CY2023Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
26400000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
139500000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
600000
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2023Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
18000000
CY2023Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2023Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
100000
CY2022Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
100000
CY2023Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
400000
us-gaap Interest Expense Debt
InterestExpenseDebt
800000
CY2023Q2 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.1144
us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.1119
CY2023Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
100000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
200000
CY2022Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
600000
us-gaap Interest Expense Debt
InterestExpenseDebt
1300000
CY2022Q2 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0807
us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0807
CY2022Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
100000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
300000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1538000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1538000
us-gaap Operating Lease Cost
OperatingLeaseCost
3076000
us-gaap Operating Lease Cost
OperatingLeaseCost
3076000
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
19000
CY2022Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
20000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
43000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
41000
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
441000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
430000
us-gaap Variable Lease Cost
VariableLeaseCost
851000
us-gaap Variable Lease Cost
VariableLeaseCost
854000
CY2023Q2 us-gaap Lease Cost
LeaseCost
1998000
CY2022Q2 us-gaap Lease Cost
LeaseCost
1988000
us-gaap Lease Cost
LeaseCost
3970000
us-gaap Lease Cost
LeaseCost
3971000
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
1500000
us-gaap Operating Lease Expense
OperatingLeaseExpense
3100000
us-gaap Operating Lease Payments
OperatingLeasePayments
3500000
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
1500000
us-gaap Operating Lease Expense
OperatingLeaseExpense
3100000
us-gaap Operating Lease Payments
OperatingLeasePayments
800000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y3M18D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y9M18D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.108
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.108
CY2023Q2 stro Percentage Of Interest Rate Amortize Liability
PercentageOfInterestRateAmortizeLiability
0.163
CY2023Q2 stro Non Cash Interest Expense On Deferred Royalty Obligation
NonCashInterestExpenseOnDeferredRoyaltyObligation
400000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
4530000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
9219000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
9533000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
8994000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
8289000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
40565000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
8105000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
32460000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5934000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
26526000
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7325000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3080000
CY2023Q2 stro Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
19593000
CY2022Q4 stro Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
14764000
us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote per share
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
16630903
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
13804406
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60339475
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60339475
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46957196
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6661000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6696000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12682000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13670000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
200000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
500000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.003
CY2023Q2 us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
2500000
us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
2500000
CY2023Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-38524000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-26012000
us-gaap Net Income Loss
NetIncomeLoss
-88574000
us-gaap Net Income Loss
NetIncomeLoss
-65122000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46957196
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59535918
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59535918
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46729663
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46729663
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.39
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13894655
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11531291

Files In Submission

Name View Source Status
0000950170-23-041416-index-headers.html Edgar Link pending
0000950170-23-041416-index.html Edgar Link pending
0000950170-23-041416.txt Edgar Link pending
0000950170-23-041416-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
stro-20230630_cal.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
stro-20230630.htm Edgar Link pending
stro-20230630.xsd Edgar Link pending
stro-ex10_1.htm Edgar Link pending
stro-ex10_2.htm Edgar Link pending
stro-ex31_1.htm Edgar Link pending
stro-ex31_2.htm Edgar Link pending
stro-ex32_1.htm Edgar Link pending
stro-ex32_2.htm Edgar Link pending
stro-20230630_def.xml Edgar Link unprocessable
stro-20230630_lab.xml Edgar Link unprocessable
stro-20230630_pre.xml Edgar Link unprocessable
stro-20230630_htm.xml Edgar Link completed